Table 1.
Baseline characteristics of study population
| Variable | TBI-based | Bu-based | P-value |
|---|---|---|---|
| Number of patients | 819 | 299 | |
| Patient age | 0.004 | ||
| 18-49 | 683 (83) | 226 (76) | |
| 50-60 | 136 (17) | 73 (24) | |
| Median (range) | 37 (18-60) | 38 (18-60) | 0.04 |
| Male gender | 485 (59) | 172 (58) | 0.61 |
| KPS≥90% | 552 (67) | 216 (72) | 0.015 |
| B lineage | 677 (83) | 247 (83) | 0.11 |
| TKI pre-HCT (for Ph+) | 150 (50) | 86 (73) | <0.001 |
| White blood count at diagnosis | 0.86 | ||
| <= 30 | 443 (54) | 157 (53) | |
| 31 - 100 | 111 (14) | 39 (13) | |
| > 100 | 105 (13) | 44 (15) | |
| Missing | 160 (20) | 59 (20) | |
| Extra-medullary disease present at diagnosis | 111 (14) | 40 (13) | 0.98 |
| Cytogenetics groupinga at diagnosis | 0.03 | ||
| Poor, Ph+ | 300 (37) | 118 (39) | |
| Poor, Ph− | 121 (15) | 44 (15) | |
| Other | 314 (38) | 123 (41) | |
| Missing | 84 (10) | 14 (5) | |
| CR1 prior to HCT | 610 (74) | 223 (75) | 0.97 |
| Time to achieve CR1 | 0.003 | ||
| <=8 weeks | 449 (62) | 133 (56) | |
| >8 weeks | 309 (38) | 133 (44) | |
| Time from CR1 to HCT (for CR1) | 0.002 | ||
| 0-6 months | 749 (88) | 259 (80) | |
| >6 months | 70 (12) | 40 (20) | |
| Conditioning regimen | |||
| TBI+VP16 | 204 (25) | 0 | |
| TBI+Cy | 615 (75) | 0 | |
| Bu+Flu | 0 | 124 (41) | |
| Bu+Clo | 0 | 91 (30) | |
| Bu+Mel | 0 | 38 (13) | |
| Bu+Cy | 0 | 46 (15) | |
| Pharmacokinetics for Bu dosing | N/A | 240 (80) | |
| Dose of TBI ≥13Gy fractionated | 305 (37) | N/A | |
| CNS radiation boost administered | 67 (8) | N/A | |
| Testicular radiation boost administered | 72 (9) | N/A | |
| HLA-identical sibling donor | 408 (50) | 166 (56) | 0.09 |
| Peripheral blood graft | 623 (76) | 251 (84) | 0.005 |
| GVHD prophylaxis | <0.001 | ||
| Tacrolimus-based | 593 (72) | 267 (89) | |
| Cyclosporine-based | 207 (25) | 23 (8) | |
| Others | 4 (1) | 6 (2) | |
| Missing | 15 (2) | 3 (1) | |
| ATG/alemtuzumab given | 108 (12) | 69 (23) | <0.001 |
| Post-HCT preemptive TKI (for Ph+) | 86 (33) | 59 (55) | <0.001 |
| Year of HCT | <0.001 | ||
| 2005-2010 | 573 (70) | 158 (53) | |
| 2011-2015 | 246 (30) | 141 (47) | |
| Median follow-up of survivors (range), months | 63 (3-125) | 43 (3-98) |
a
Poor cytogenetics: complex (>= 3 abnormalities), t(9;22), t(4;11), hypodiploid (<46).
Abbreviations: TBI, total body irradiation; BU, busulfan; KPS, Karnofsky performance status; TKI, tyrosine kinase inhibitor; HCT, hematopoietic cell transplantation; Ph, Philadelphia chromosome; CR, complete remission; VP16, etoposide; Cy, cyclophosphamide; Flu, fludarabine; Clo, clofarabine; Mel, melphalan; Gy, gray; CNS, central nervous system; HLA, hematopoietic cell transplantation; GVHD, graft-versus-host disease; ATG, anti-thymocyte globulin; N/A, not applicable